Immunohistochemical studies of conjunctival nevi and melanomas

Archives of Ophthalmology

Volumn 128, Issue 2, 2010, Pages 174-183

  Jakobiec, Frederick A ^a   Bhat, Pooja ^a   Colby, Kathryn A ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD45 ANTIGEN; HMB 45 PROTEIN; KI 67 ANTIGEN; MELAN A; PARAFFIN; PROTEIN S 100; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CANCER DIAGNOSIS; CELL JUNCTION; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CONJUNCTIVA EPITHELIUM; CONJUNCTIVA NEVUS; CONJUNCTIVA TUMOR; CONTROLLED STUDY; CYTOPLASM; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; IMMUNOREACTIVITY; LYMPHOCYTE; LYMPHOCYTIC INFILTRATION; MALE; MELANOCYTE; MELANOMA; NEVUS; NEVUS CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SKIN NODULE; TISSUE SECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD45; ANTIGENS, NEOPLASM; CHILD; CONJUNCTIVAL NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; NEVUS, PIGMENTED; RETROSPECTIVE STUDIES; S100 PROTEINS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 76349116288     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2009.394     Document Type: Article

References (47)

1. Blessing K, Sanders DS, Grant JJ. Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. Histopathology. 1998;32(2):139-146.
2. Orosz Z. Melan-A/Mart-1 expression in various melanocytic lesions and in nonmelanocytic soft tissue tumours. Histopathology. 1999;34(6):517-525.
3. Evans MJ, Sanders DS, Grant JH, Blessing K. Expression of Melan-A in Spitz, pigmented spindle cell nevi, and congenital nevi: comparative immunohistochemical study. Pediatr Dev Pathol. 2000;3(1):36-39.
4. Xu X, Chu AY, Pasha TL, Elder DE, Zhang PJ. Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas. Am J Surg Pathol. 2002;26(1):82-87.
5. Li LX, Crotty KA, McCarthy SW, Palmer AA, Kril JJ. A zonal comparison of MIB1-Ki67 immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol. 2000;22(6):489-495.
6. Kaleem Z, Lind AC, Humphrey PA, et al. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas? Mod Pathol. 2000;13(3):217-222.
7. Bergman R, Malkin L, Sabo E, Kerner H. MIB-1 monoclonal antibody to determine proliferative activity of Ki-67 antigen as an adjunct to the histopathologic differential diagnosis of Spitz nevi. J Am Acad Dermatol. 2001;44(3):500-504.
8. Vollmer RT. Use of Bayes rule and MIB-1 proliferation index to discriminate Spitz nevus from malignant melanoma. Am J Clin Pathol. 2004;122(4):499-505.
9. Lohmann CM, Iversen K, Jungbluth AA, Berwick M, Busam KJ. Expression of melanocyte differentiation antigens and Ki-67 in nodal nevi and comparison of Ki-67 expression with metastatic melanoma. Am J Surg Pathol. 2002;26(10):1351-1357.
10. Harvell JD, Bastian BC, LeBoit PE. Persistent (recurrent) Spitz nevi: a histopathologic, immunohistochemical, and molecular pathologic study of 22 cases. Am J Surg Pathol. 2002;26(5):654-661.
11. Lebe B, Pabuccuoglu U, Ozer E. The significance of Ki-67 proliferative index and cyclin D1 expression of dysplastic nevi in the biologic spectrum of melanocytic lesions. Appl Immunohistochem Mol Morphol. 2007;15(2):160-164.
12. Boyd AS, Shakhtour B, Shyr Y. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases. J Am Acad Dermatol. 2008;58(5):750-754.
13. Cassarino DS, Cabral ES, Kartha RV, Swetter SM. Primary dermal melanoma: distinct immunohistochemical findings and clinical outcome compared with nodular and metastatic melanoma. Arch Dermatol. 2008;144(1):49-56.
14. Glasgow BJ, McCall LC, Foos RY. HMB-45 antibody reactivity in pigmented lesions of the conjunctiva. Am J Ophthalmol. 1990;109(6):696-700.
15. McDonnell JM, Sun YY, Wagner D. HMB-45 immunohistochemical staining of conjunctival melanocytic lesions. Ophthalmology. 1991;98(4):453-458.
16. Steuhl KP, Rohrbach JM, Knorr M, Thiel HJ. Significance, specificity, and ultrastructural localization of HMB-45 antigen in pigmented ocular tumors. Ophthalmology. 1993;100(2):208-215.
17. Heegaard S, Jensen OA, Prause JU. Immunohistochemical diagnosis of malignant melanoma of the conjunctiva and uvea: comparison of the novel antibody against melan-A with S100 protein and HMB-45. Melanoma Res. 2000;10(4):350-354.
18. Hitzer S, Bialasiewicz AA, Richard G. Immunohistochemical markers for cytoplasmic antigens in acquired melanosis, malignant melanomas, and nevi of the conjunctiva [in German]. Klin Monatsbl Augenheilkd. 1998;213(4):230-237.
19. Sharara NA, Alexander RA, Luthert PJ, Hungerford JL, Cree IA. Differential immunoreactivity of melanocytic lesions of the conjunctiva. Histopathology. 2001;39(4):426-431.
20. Iwamoto S, Burrows RC, Grossniklaus HE, et al. Immunophenotype of conjunctival melanomas: comparisons with uveal and cutaneous melanomas. Arch Ophthalmol. 2002;120(12):1625-1629.
21. Barnhill R. Combined nevus. In: Le Boit PBG, Weedon D, Sarasin A, eds. World Health Organization Classification of Tumors: Pathology and Genetics of Skin Tumors. Lyon, France: IARC Press; 2006:100-102.
22. Magro CM, Crowson AN, Mihm MC. Unusual variants of malignant melanoma. Mod Pathol. 2006;19(suppl 2):S41-S70.
23. Jakobiec FA, Folberg R, Iwamoto T. Clinicopathologic characteristics of premalignant and malignant melanocytic lesions of the conjunctiva. Ophthalmology. 1989;96(2):147-166.
24. Folberg R, Jakobiec FA, Bernardino VB, Iwamoto T. Benign conjunctival melanocytic lesions: clinicopathologic features. Ophthalmology. 1989;96(4):436-461.
25. Jakobiec FA. The ultrastructure of conjunctival melanocytic tumors. Trans Am Ophthalmol Soc. 1984;82:599-752.
26. Liesegang TJ. Pigmented conjunctival and scleral lesions. Mayo Clin Proc. 1994;69(2):151-161.
27. Crowson AMC, Mihm M. The Melanocytic Proliferations: A Comprehensive Textbook of Pigmented Lesions. New York, NY: Wiley-Liss; 2001:417-448.
28. Wick M. Immunohistochemistry of melanocytic neoplasms. In: Dabbs D, ed. Diagnostic Immunohistochemistry. Philadelphia, PA: Churchill Livingstone/Elsevier; 2006:162-179.
29. Eagle RC Jr. Immunohistochemistry in diagnostic ophthalmic pathology: a review. Clin Experiment Ophthalmol. 2008;36(7):675-688.
30. Keijser S, Missotten GS, Bonfrer JM, de Wolff-Rouendaal D, Jager MJ, de Keizer RJ. Immunophenotypic markers to differentiate between benign and malignant melanocytic lesions. Br J Ophthalmol. 2006;90(2):213-217.
31. Pache M, Glatz-Krieger K, Sauter G, Meyer P. Expression of sex hormone receptors and cell cycle proteins in melanocytic lesions of the ocular conjunctiva. Graefes Arch Clin Exp Ophthalmol. 2006;244(1):113-117.
32. Vervaet N, Van Ginderdeuren R, Van Den Oord JJ, Foets B. A rare conjunctival Spitz nevus: a case report and literature review. Bull Soc Belge Ophtalmol. 2007;(303):63-67.
33. Chowers I, Livni N, Solomon A, et al. MIB-1 and PC-10 immunostaining for the assessment of proliferative activity in primary acquired melanosis without and with atypia. Br J Ophthalmol. 1998;82(11):1316-1319.
34. Ohara M, Sotozono C, Tsuchihashi Y, Kinoshita S. Ki-67 labeling index as a marker of malignancy in ocular surface neoplasms. Jpn J Ophthalmol. 2004;48(6):524-529.
35. Ball NJ, Golitz LE. Melanocytic nevi with focal atypical epithelioid cell components: a review of seventy-three cases. J Am Acad Dermatol. 1994;30(5, pt 1):724-729.
36. El-Gamal HM, Robinson-Bostom L, Saddler KD, Pan T, Mihm MC. Compound melanocytic nevi with granular cell changes. J Am Acad Dermatol. 2004;50(5):765-766.
37. Jakobiec FA, Colby K, Bajart A, Saragas SJ, Moulin A. Immunohistochemical studies of atypical conjunctival nevi. Arch Ophthalmol. 2009;127(8):970-980.
38. Brownstein S, Faraji H, Jackson WB, Font RL. Conjunctival melanoma in children: a clinicopathologic study of 2 cases. Arch Ophthalmol. 2006;124(8):1190-1193.
39. Strempel I, Kroll P. Conjunctival malignant melanoma in children. Ophthalmologica. 1999;213(2):129-132.
40. Folberg R, McLean IW, Zimmerman LE. Primary acquired melanosis of the conjunctiva. Hum Pathol. 1985;16(2):129-135.
41. Sugiura M, Colby KA, Mihm MC Jr, Zembowicz A. Low-risk and high-risk histologic features in conjunctival primary acquired melanosis with atypia: clinicopathologic analysis of 29 cases. Am J Surg Pathol. 2007;31(2):185-192.
42. Ackerman AB, Sood R, Koenig M. Primary acquired melanosis of the conjunctiva is melanoma in situ. Mod Pathol. 1991;4(2):253-263.
43. Folberg R, Jakobiec FA, McLean IW, Zimmerman LE. Is primary acquired melanosis of the conjunctiva equivalent to melanoma in situ? Mod Pathol. 1992;5(1):2-8.
44. Damato B, Coupland SE. Conjunctival melanoma and melanosis: a reappraisal of terminology, classification and staging. Clin Experiment Ophthalmol. 2008;36(8):786-795.
45. Zamir E, Mechoulam H, Micera A, Levi-Schaffer F, Pe'er J. Inflamed juvenile conjunctival naevus: clinicopathological characterisation. Br J Ophthalmol. 2002;86(1):28-30.
46. Thiagalingam S, Johnson MM, Colby KA, Zembowicz A. Juvenile conjunctival nevus: clinicopathologic analysis of 33 cases. Am J Surg Pathol. 2008;32(3):399-406.
47. Furusato E, Hidayat AA, Man YG, Auerbach A, Furusato B, Rushing EJ. WT1 and Bcl2 expression in melanocytic lesions of the conjunctiva: an immunohistochemical study of 123 cases. Arch Ophthalmol. 2009;127(8):964-969.